NIH's early termination of the AIM-HIGH trial does further damage to combination therapy for increasing HDL cholesterol and lowering triglycerides in patients with well-controlled LDL cholesterol.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
